Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Non-Current Assets (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Non-Current Assets data on record, last reported at $48.3 million in Q4 2025.

  • For Q4 2025, Non-Current Assets rose 6.95% year-over-year to $48.3 million; the TTM value through Dec 2025 reached $182.1 million, up 16.27%, while the annual FY2025 figure was $48.3 million, 6.95% up from the prior year.
  • Non-Current Assets reached $48.3 million in Q4 2025 per CLDX's latest filing, up from $44.1 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $48.3 million in Q4 2025 and bottomed at $33.3 million in Q1 2022.
  • Average Non-Current Assets over 5 years is $37.8 million, with a median of $35.0 million recorded in 2022.
  • Peak YoY movement for Non-Current Assets: crashed 36.33% in 2021, then surged 36.37% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $33.8 million in 2021, then grew by 3.63% to $35.0 million in 2022, then dropped by 3.16% to $33.9 million in 2023, then skyrocketed by 33.14% to $45.2 million in 2024, then rose by 6.95% to $48.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $48.3 million in Q4 2025, $44.1 million in Q3 2025, and $44.0 million in Q2 2025.